Purified mammalian cell binding receptor for bacterial lipopolysaccharide endotoxin and monoclonal antibody
US5045466A · kind A · utility
9Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 7, 1989 |
| Grant date | Sep 3, 1991 |
| Priority date | — |
| Expiry date | Jul 7, 2009 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/864
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention is directed to hydridoma cell lines and the monoclonal antibodies produced by the cell lines, where the monoclonal antibodies specifically bind to the lipopolysaccharide endotoxin binding receptor of mammalian cells. Specifically, the monoclonal antibodies binds to a cell receptor which has a molecular mass of 80 kilodaltons, and is specific for the lipid A component of the lipopolysaccharide endotoxin. The monoclonal antibodies are specific for a carbohydrate component of the binding receptor in one instance, and for a protein/peptide receptor in another.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.